Cochlear And 2 Australian Healthcare Stocks To Watch
Hotter than expected US inflation and the resulting sell-off in global AI and tech stocks have pushed many investors to rethink where they want steadier exposure. Australian healthcare leaders, with established operations and solid balance sheets, can appear relatively sheltered from swings tied to AI hype and interest rate fears. This article highlights three healthcare stocks from our screener that focus on quality, resilience and long term potential.
The three stocks below are just a starting sample from this theme, and the full screen surfaced 9 more healthcare companies with equally compelling narratives that are not covered here. To go deeper on this idea, head straight into the Best Healthcare Stocks screener to identify, compare and analyze the highest conviction opportunities that fit your criteria.
Cochlear (ASX:COH)
Cochlear is a pure play on implantable hearing solutions, with its cochlear implant systems and connected care tools anchoring its relevance to the Best Healthcare Stocks theme for reliable medical equipment exposure.
Cochlear generates A$2.35b from implantable hearing devices and related products and has a market value of about A$8.4b, reflecting a large scale specialist in hearing health within global healthcare equipment.
"The launch of the Nexa system, the world's first smart cochlear implant, is expected to drive market share gains in developed markets due to strong differentiation, surgeon enthusiasm, and planned price increases, likely boosting revenue and average selling prices (ASPs) starting in 2H FY26."
What investors really need to watch is how one unresolved pressure on profitability plays out against those higher expected device volumes.
That profitability question is the crux, and the full narrative for Cochlear explains how Cochlear could balance pricing, volumes and capital allocation as Nexa adoption accelerates worldwide.
Mesoblast (ASX:MSB)
Mesoblast is a pure regenerative medicine play within the Best Healthcare Stocks theme, using mesenchymal lineage cell therapies like Ryoncil, Remestemcel L and Revascor to target severe inflammatory and cardiovascular conditions. The company is generating about US$120 million from developing and commercializing its allogeneic cellular medicines platform and carries a market value near A$2.5b.
Mesoblast provides direct exposure to high conviction cell therapies, where a focused platform, clinical partnerships and early commercial traction can matter more than headline volatility.
"The first and only FDA approved mesenchymal stromal cell product in the U.S., Ryoncil, together with over 1,100 patents and established commercial scale manufacturing, positions Mesoblast to benefit if cell therapies gain wider medical adoption."
The key issue from here is how quickly that early foothold can broaden into larger indications without stretching funding too thin.
If that funding question is on your mind, the full narrative for Mesoblast explains how Mesoblast could either accelerate or stall as cell therapy adoption broadens.
Neuren Pharmaceuticals (ASX:NEU)
Neuren Pharmaceuticals focuses on treatments for neurological disorders, with approved Rett syndrome therapy DAYBUE anchoring its Best Healthcare Stocks theme exposure while A$69.5 million in commercial product revenue from the United States supports an A$2.4b market value.
For investors looking at neurology focused healthcare, Neuren Pharmaceuticals offers a pure play on commercialised rare disease treatment with DAYBUE and a pipeline of follow on programs that could extend that reach if the science and execution both cooperate.
"Planned expansion into international markets, such as Canada, Europe, and Japan, offers significant long-term growth prospects and additional revenue streams due to higher royalty rates outside the U.S."
What really matters from here is how one pressure on future earnings quality collides with expectations already baked into Neuren Pharmaceuticals shares.
That pressure point is exactly where the full narrative for Neuren Pharmaceuticals shows whether Neuren Pharmaceuticals' royalty engine is quietly accelerating or if expectations risk getting ahead of the story.
Seeking Alternatives Beyond Healthcare?
Fresh themes keep breaking out while older stories lose momentum. Review these ideas while they may still be flying under the radar.
- Identify cash-generative businesses before momentum headlines focus on them by running your own shortlist from the list of solid balance sheet and fundamentals (12 results).
- Explore early strength in future-facing miners while sentiment is still mixed by working through the curated 32 best rare earth metal stocks.
- Track high growth potential while maintaining attention to financial discipline by scanning the hand-picked 15 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com